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Proinflammatory isoforms of IL-32 
as novel and robust biomarkers for 
control failure in HIV-infected slow 
progressors
Mohamed El-Far1, Pascale Kouassi1,2, Mohamed Sylla1, Yuwei Zhang1,2, Ahmed Fouda1, 
Thomas Fabre1,2, Jean-Philippe Goulet3, Julien van Grevenynghe4, Terry Lee5, Joel Singer5, 
Marianne Harris6, Jean-Guy Baril7, Benoit Trottier8, Petronela Ancuta1,2, Jean-Pierre Routy9, 
Nicole Bernard10, Cécile L. Tremblay1,2  & Investigators of the Canadian HIV+ Slow Progressor 
Cohort #
HIV-infected slow progressors (SP) represent a heterogeneous group of subjects who spontaneously 
control HIV infection without treatment for several years while showing moderate signs of disease 
progression. Under conditions that remain poorly understood, a subgroup of these subjects experience 
failure of spontaneous immunological and virological control. Here we determined the frequency of 
SP subjects who showed loss of HIV control within our Canadian Cohort of HIV+ Slow Progressors and 
identified the proinflammatory cytokine IL-32 as a robust biomarker for control failure. Plasmatic levels 
of the proinflammatory isoforms of IL-32 (mainly β and γ) at earlier clinic visits positively correlated with 
the decline of CD4 T-cell counts, increased viral load, lower CD4/CD8 ratio and levels of inflammatory 
markers (sCD14 and IL-6) at later clinic visits. We present here a proof-of-concept for the use of IL-32 as a 
predictive biomarker for disease progression in SP subjects and identify IL-32 as a potential therapeutic 
target.
Infection with the human immunodeficiency virus (HIV) remains a global health challenge despite the remark-
able success of combined antiretroviral therapy (cART) to significantly reduce both mortality and morbidity in 
the infected population. However, even with near-complete viral suppression by the current classes of treatment, 
curing HIV infection remains unachievable and patients must adhere to lifelong treatment. This is largely due 
to the persistence of replication-competent HIV in latent viral reservoirs that are resistant to the current regi-
mens, and to the capacity of these reservoirs to reinitiate infection upon cessation of therapy1–3. Both long-term 
exposure to treatment and persistence of viral infection are likely to have a clinical cost as evidenced by the 
treatment-associated toxicities, persistent inflammation, immune dysfunction, cardiovascular and neurologic 
disorders and pre-mature aging seen in treated subjects4,5. Furthermore, the failure of different vaccine trials 
aiming to prevent HIV infection6 and the partial success of others7 together highlight the critical need for novel 
and unconventional therapies. For these reasons, there is a renewed interest in novel immunological strategies 
that aim to eliminate viral reservoirs and to strengthen immune responses able to control viral replication after 
infection, thereby limiting ART exposure and achieving a functional cure8,9.
Natural and sustained immunological responses are indeed observed in a subset of HIV-infected individu-
als who spontaneously control HIV infection without ART for several years while showing moderate signs of 
disease progression. These subjects represent the HIV-infected slow progressors (SP), including the rare Elite 
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Controller (EC) subgroup, which constitutes less than 1% of the HIV-infected population10,11. The low rate of 
transmission and slow disease progression associated with lower levels of HIV-RNA and prolonged high CD4+ 
T-cell counts make the study of these SP subjects of particular interest to inform and fuel potential strategies that 
support a functional cure for HIV infection12–14. Genome-wide association studies have implicated the major 
histocompatibility complex (MHC) class I region in natural control of HIV viral load (VL)15. A higher frequency 
of HIV-infected subjects carrying the MHC class I alleles such as HLA-B*27 and HLA-B*57 was observed in SPs 
compared to typical progressors (TP). Cytotoxic CD8+ T-cells that recognize complexes of these protective MHC 
class I antigens and HIV epitopes are particularly effective at controlling HIV replication16–19. However, many SP 
subjects do not carry protective MHC class I alleles20. Furthermore, some SPs, including those carrying protec-
tive MHC class I alleles, fail to maintain long-term control and eventually exhibit HIV disease progression21,22. 
This suggests that other immunological and virological parameters are also involved in the remarkable capacity 
of these SP subjects to control HIV infection and that these parameters may not be sustained forever. Examining 
host and viral parameters in SPs before and after loss of control, provides an opportunity to identify the mech-
anisms underlying enhanced immunological and virological control and its loss in these SPs who begin to pro-
gress. With this in mind, the Canadian Cohort of HIV+ Slow Progressors (CCHSP) was established in Canada to 
better characterize correlates of HIV control among both aviremic and viremic SPs.
In the current study we investigated the rate of CD4+ T-cell decline in subgroups of the CCHSP, which differed 
from each other in the level of virological control, and identified subjects who experienced loss of virological 
control accompanied by significant declines in CD4+ T-cell counts. We employed genome-wide transcriptional 
analysis on peripheral blood from these later subjects, before and after loss of control, to identify and validate 
biomarkers and predictive factors associated with disease progression in HIV-infected SP.
Results
Rate of CD4 decline in HIV-infected SPs. HIV-infected SPs included Elite controllers (EC, VL ≤ 50 
HIV RNA copies/ml of plasma and CD4 counts > 500 cells/mm3 at study entry), Virologic Controllers, (VC, VL 
51–3,000 copies/ml of plasma and CD4 counts > 500 cells/mm3 at study entry) and Non-virologic Controllers 
(NVC, VL > 3,000 copies/ml of plasma and CD4 counts > 500 cells/mm3, for > 7 years) (Table 1). Using the 
definitions of HIV control as described above, there were n = 45 EC, n = 68 VC and n = 33 NVC in our cohort 
(demographic and disease history characteristics of these subgroups are presented in Supplementary Table S1). 
A control group of Typical Progressor (TP) HIV-infected subjects (n = 490 subjects) was used for comparisons. 
These subjects were enrolled in the Montreal Primary Infection (PI) or PRIMO cohort, which enrolls individuals 
during the first year of infection and follows them for up to 2 years (Supplementary Table S1).
By using mixed effects regression analysis on historical and prospective data, we observed that the estimated 
rate of CD4 decline varies according to the SP study subgroups defined by VL. EC, VC and NVC subjects exhib-
ited annual rates of CD4 decline of 11.3, 15.4 and 21.2 cells/mm3. The rate of CD4 count change for each of these 
subgroups was significantly less than “zero” for each of these subject groups (p = 0.031, p < 0.001 and p < 0.001 
for EC, VC and NVC, respectively) (Fig. 1a). However, the rates of CD4 decline between EC, VC and NVC were 
not significantly different (Fig. 1b). The TP group had the highest rate of CD4 decline with an annual loss of 78 
cells/mm3 (p < 0.001) and represented a faster decline compared to that of each of the SP subgroups (Fig. 1b). 
We also evaluated the effect of a variety of baseline covariates (gender (Supplementary Fig. S1a), age at diagnosis 
(Supplementary Fig. S1b), race (Supplementary Fig. S2) and modes of transmission (Supplementary Fig. S3)) on 
the CD4 slope. None of these covariates were found to have a significant impact on the CD4 slope (p-values were 
> 0.2 for all the covariates in the univariate regression analysis and thus covariates were not included in the main 
analysis.
At the time of analysis, HLA typing data were available for 42/45 of EC, 63/68 of VC and 30/33 of NVC. The 
frequency of subjects possessing protective alleles within each SP subgroup is presented in Table 2. Within the SP 
cohort, the presence of HLA-B*27 protective allele was found to differ significantly between SP subgroups with 
the EC subjects having the highest prevalence (28.6%) compared to 17.5% and 3.3% for VC and NVC, respec-
tively (Fisher’s exact test p = 0.022). Of interest, 17.8% (24/135) of all SP subjects carried the protective HLA-B*27 
allele compared to 8.1% (37/455) of TP (p = 0.001, Fisher’s exact test). HLA-B*57 was carried by 22.2% (30/135) 
of SP compared to 5.5% (25/455) of TPs (p < 0.001, Fisher’s exact test).
Identification of SP subjects who experience failure of immunological and virological con-
trol. We determined the frequency of SP subjects who experienced HIV disease progression by monitoring 
longitudinal CD4 count and VL changes. We defined the failure of control with a primary criterion of a negative 
slope of CD4 count (significantly different from “zero”) combined with a significant increase in VL based on 
historical and prospective clinical records from the time of infection to time of the last recorded clinic visit for all 
Slow Progressor subgroups/number of subjectsA
CD4+ T-cell count at 
baseline
HIV-RNA viral load 
(VL) at baseline
Time since 
infection ARTB
Elite controller (n = 45) > 500 cells mm3 ≤ 50 copies/ml Any NO
Virologic controller (n = 68) > 500 cells mm3 51–3000 copies/ml Any NO
Non-Virologic controller(n = 33) > 500 cells mm3 > 3000 copies/ml > 7 years NO
Table 1. Classification and clinical characteristics of HIV-infected slow progressor subgroups. ASlow 
progressor: HIV+ study participant meeting any of shown definitions and having no signs of AIDS. 
BAntiretroviral treatment.
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subjects within the SP cohort (subjects having < 3 clinic visits were excluded from the analysis, n = 4). As shown 
in Table 3 and Fig. 2a, only 17 subjects (EC (n = 1/42, 2.4%), VC (n = 7/67, 10.5%) and NVC (n = 9/33, 27.3%)) 
had a significant (p < 0.05) negative CD4 count slope combined with a significant (p < 0.05) positive slope for 
VL. These statistics were determined on a combination of historical (since the time of infection and prior to study 
entry) and actual clinical data (following enrolment to the study) from the SP subgroups. However, to identify 
clinical visits, after enrolment to the study, from which biological samples were available and could be used for 
further experimental investigation on failure of control, both CD4 counts and VL were measured from two lon-
gitudinal clinic visits on n = 53 subjects including a representative number from each subgroup, EC (n = 17), VC 
(n = 25) and NVC (n = 11). Visit 1 (V1) corresponded to a time point close to study entry at which CD4 counts 
were ≥ 500 CD4+ T-cells/mm3 and VL within the range used to categorize subjects as EC, VC or NVC. Visit 2 
(V2) corresponded to an average ± standard deviation time interval of 30 ± 16, 34 ± 25 and 33 ± 15 months for 
EC, VC and NVC, respectively. CD4 counts for EC, VC and NVC at V1 were 848 ± 234, 705 ± 144 and 708 ± 107 
Figure 1. Decline of CD4+ T-cell counts in the different slow progressor (SP) subgroups. (a) Mixed effects 
regression analysis on CD4 decline for Elite controllers (n = 45) (Left upper panel), Virologic controllers 
(n = 68) (Right upper panel), Non-virologic controllers (n = 33) (Left lower panel) compared to Typical 
progressors (Primo) (n = 490) (Right lower panel). Black lines are the individual CD4 profiles and colored lines 
are the estimated CD4 decline from the mixed effects regression analysis. (b) Slope of CD4 decline from the 
same 4 groups of subjects as in A.
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cells/mm3, respectively, and average Log10 VLs were 1.66 ± 0.05, 2.65 ± 0.51 and 4.17 ± 0.32, respectively. At V2, 
CD4 counts for EC, VC and NVC were 725 ± 144, 622 ± 211 and 505 ± 192 cells/mm3, respectively, and average 
Log10 VLs were 1.8 ± 0.44, 3.1 ± 0.76 and 4.48 ± 0.43, respectively. A decline in CD4 counts and an increase in VL 
was observed for EC, VC and NVC but was significant for only the VC and NVC subgroups (p = 0.027 and 0.018, 
respectively for CD4 count, Fig. 2b, Upper panels, and p = 0.022 and p = 0.019, respectively for VLs, Fig. 2b, 
Lower panels). By fixing a threshold for the loss of control between the two visits as a decline in CD4 counts ≥ 100 
cells/mm3 combined with any increase in the Log10 VL, only 2 of 17 (11.7%) EC subjects, 8 of 25 (32%) VC, and 7 
of 11 (63.6%) of NVC for a total of 17 of 53 (32%) SP subjects met the criteria for disease progression (Fig. 2c). Six 
out of these 17 subjects were also identified as having a CD4 count decline with a VL increase and thus this was 
evidence of HIV disease progression based on their historical and prospective data (Table 3) and Fig. 2a.
All SP
Elite 
(n = 42)
Virologic 
(n = 63)
Non-virologic 
(n = 30) P valueA
All SP 
(n = 135) Primo(n = 455) P valueB
Num of protective alleles, n (%) 0.525 < 0.001
 0 13 (31.0) 22 (34.9) 15 (50.0) 50 (37.0) 261 (57.4)
 1 22 (52.4) 33 (52.4) 12 (40.0) 67 (49.6) 180 (39.6)
 2 7 (16.7) 8 (12.7) 3 (10.0) 18 (13.3) 14 (3.1)
With protective alleles, n (%) 0.229 < 0.001
 No 13 (31.0) 22 (34.9) 15 (50.0) 50 (37.0) 261 (57.4)
 Yes 29 (69.0) 41 (65.1) 15 (50.0) 85 (63.0) 194 (42.6)
HLA type, n (%)
 B*13 2 (4.8) 5 (7.9) 3 (10.0) 0.702 10 (7.4) 8 (1.8) 0.001
 B*14 3 (7.1) 10 (15.9) 6 (20.0) 0.258 19 (14.1) 43 (9.5) 0.124
 B*27 12 (28.6) 11 (17.5) 1 (3.3) 0.022 24 (17.8) 37 (8.1) 0.001
 B*38 1 (2.4) 0 (0.0) 0 (0.0) 0.533 1 (0.7) 18 (4.0) 0.063
 B*51 4 (9.5) 5 (7.9) 1 (3.3) 0.640 10 (7.4) 65 (14.3) 0.035
 B*57 11 (26.2) 15 (23.8) 4 (13.3) 0.397 30 (22.2) 25 (5.5) < 0.001
 B*58 3 (7.1) 2 (3.2) 2 (6.7) 0.604 7 (5.2) 12 (2.6) 0.141
 B*81 0 (0.0) 1 (1.6) 1 (3.3) 0.492 2 (1.5) 0 (0.0) 0.052
 3DL1*h/*y + B*57 3 (7.9) 8 (14.0) 3 (10.3) 0.717 14 (11.3) 9 (2.0) < 0.001
Table 2. Proportion of subjects with different HLA types. Genotype data missing for 11 SP subjects and 35 
subjects in the Primo cohort Protective alleles - among HLA-B*13, B*14, B*27, B*38, B*51, B*57, B*58 and 
B*81 P values are based on Fisher’s exact test/Chi square test as appropriate AComparison between the SP. 
BComparison between all SP and Primo.
Subject ID
Time Since 
infection (Years)
CD4 decline (Cells/
mm3/year ± SD) P value
Viral load increase 
(HIV copies/year ± SD) P value
EC
 218001 5.19 − 88.59 ± 40.19 0.0478 25.41 ± 8.83 0.0139
VC
 102018 14.74 − 24.92 ± 3.40 < 0.0001 55.37 ± 25.86 0.0393
 104001 7.55 − 37.67 ± 11.67 0.008 253.6 ± 39.98 < 0.0001
 104002 11.41 − 33.10 ± 7.36 0.0001 3355 ± 473.2 < 0.0001
 104003 22.29 − 21.52 ± 3.76 < 0.0001 3350 ± 748.3 0.0012
 110004 15.78 − 31.21 ± 3.45 < 0.0001 233.5 ± 61.59 0.001
 205002 6.59 − 33.80 ± 14.10 0.031 919.5 ± 230.4 0.0013
 501008 6.64 − 49.36 ± 16.05 0.0077 163.6 ± 60.05 0.0164
NVC
 104008 13.37 − 28.64 ± 4.76 < 0.0001 11270 ± 3028 0.0008
 105003 10.3 − 44.14 ± 8.13 < 0.0001 21120 ± 7188 0.0056
 106006 18.28 − 30.46 ± 3.91 < 0.0001 3952 ± 438.8 < 0.0001
 108001 10.51 − 74.19 ± 13.27 0.0001 7022 ± 2666 0.0218
 109003 13.25 − 18.45 ± 4.22 0.0002 1467 ± 335.5 0.0002
 109007 17.1 − 23.41 ± 3.81 < 0.0001 5589 ± 958.2 < 0.0001
 110001 13.39 − 69.76 ± 9.35 < 0.0001 2780 ± 652.9 0.0004
 110005 15.6 − 31.19 ± 4.30 < 0.0001 1609 ± 443.1 0.0015
 401010 8.24 − 64.35 ± 14.02 0.0001 4918 ± 1588 0.0045
Table 3.  Rate of CD4 decline and increased viral load in subjects falling control.
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At the time of analysis, HLA typing was available for 15 out of the 17 SP subjects losing control between V1 
and V2. Of these, 7 subjects (46%) had at least one of the protective HLA class I alleles, HLA-B*27, HLA-B*51 or 
HLA-B*57 (Supplementary Table S2).
Figure 2. Longitudinal determination of CD4+ T-cell counts and viral load (VL) of HIV-infected SP 
subgroups. (a) Frequency of EC, VC and NVC subjects with statistically significant negative slopes for CD4 
decline and increased VL calculated on the total number of visits since infection (shown in Table 3). (b) CD4 
counts (Upper panels) and Log10 VL (Lower panels) in EC (n = 17), VC (n = 25) and NVC (n = 11) at two clinic 
visits, V1 (all subjects having CD4 counts ≥ 500 CD4+ T-cells/mm3 and VL that corresponds to criteria used 
to classify each of the subgroups) and V2 (an average time interval from V1 of 30 ± 16, 34 ± 25 and 33 ± 15 
months for EC, VC and NVC, respectively). (c) CD4 counts (Left panel) and Log10 VL (Middle panel) at V1 and 
V2 for SP subjects who lost HIV control (CD4 count decrease of ≥ 100 cells/mm3 combined with any increase 
in Log10 VL). Right panel: Frequencies of EC, VC and NVC subjects losing control between V1 and V2 (EC 
n = 2/17, VC n = 8/25, and NVC n = 7/11). P values were calculated by non-parametric paired two-tail test 
(Wilcoxon) in B and C. EC = Elite Controller; VC = Virologic Controllers; NVC = Non Virologic Controllers.
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Together these data showed that the EC subjects are more resistant to disease progression than VC and NVC 
subjects. These results also revealed that that loss of control occurs in SP subjects despite carrying protective HLA 
alleles.
Identification of a molecular signature associated with failure of control in SP subjects. To 
gain further insight into the potential mechanisms that govern the loss of immunological (CD4 counts) and 
HIV control (viral load), we identified 5 subjects (VC, n = 2 and NVC, n = 3) who experienced combined loss 
of CD4 counts (average loss of 211 CD4+ T-cells/mm3) and increased VL (average increase of 20 fold) between 
V1 and V2 (visits following study entry selected as described in the previous section). Peripheral blood mon-
onuclear cells (PBMCs) collected from these subjects at V1 and V2, before and after loss of control, respec-
tively, were used for genome-wide transcriptional profiling using the Illumina microarray technology. Our 
analysis identified 1,381 probe sets corresponding to 1,268 genes that were differentially expressed between V1 
and V2 (p-value < 0.05). By applying a cut-off fold change (FC) of 1.3, we identified 207 genes down-regulated 
and 83 genes up-regulated at V2 compared to V1 among the differentially expressed genes. Of note, among the 
down-regulated genes, several members of the innate antiviral responses were identified such as APOBEC3G 
(FC = − 1.4, p = 0.03), APOBEC3F (FC = − 1.32, p = 0.012), CCL5 (FC = − 1.34, p = 0.001) and IL-32 (alpha 
and delta isoforms) (FC = − 1.7, p = 0.0007 and FC = − 1.4, p = 0.022, respectively) (Fig. 3a). Other transcripts 
previously linked to T-cell activation such as CD160, ITK and the IL-7 receptor (IL-7R) also showed a marked 
decrease (Supplementary Fig. S4).
Of these modulated genes, down-regulation of IL-32α and δ isoforms at V2 was of particular interest as 
IL-32 was previously shown to play an intracellular antiviral role, mainly mediated by interferon-induced genes 
(ISGs)23,24. Consistently, we also observed a significant increase in several ISGs such as IFI27, IFI30, IFI35, 
IFITM3 and OSA1 (Fig. 3a), suggesting an ongoing interferon response, likely due to the increased HIV repli-
cation. Since the IL-32α and δ isoforms are down-modulated between V1 and V2 this suggests that they are not 
likely involved in mediating expression of the interferon-induced signalling linked to HIV infection.
In accordance with the decrease of IL-32α mRNA in our transcriptomic analysis, the ELISA quantification 
of IL-32α soluble protein in plasma from EC and TP subjects compared to HIV-uninfected controls (HIVneg) 
showed significantly lower IL-32α levels (p < 0.05 and p < 0.001, respectively). There was a tendency for higher 
IL-32α levels in ECs compared to that in TPs, although the difference did not achieve statistical significance 
(Fig. 3b). Of note, we were not able to measure the IL-32δ at the protein level due to the lack of specific antibodies. 
Plasma IL-32 was further measured using a set of antibodies having the capacity to recognize the 4 prototypic 
isoforms, α , β , γ and δ (that we refer to here as total IL-32). Intriguingly, the total IL-32 levels were significantly 
higher in TPs compared to both HIVneg and EC subjects (p < 0.001 and p < 0.05, respectively, Fig. 3c). This was 
also the case for total IL-32 levels quantified in cell lysate of PBMCs collected from EC, TP and HIVneg subjects 
(Supplementary Fig. S5a). Furthermore there was a positive correlation between cell-associated and plasma levels 
of total IL-32 measured from the same subjects (Supplementary Fig. S5b). These results suggest that the IL-32 
isoforms other than IL-32α and δ , most likely the IL-32 β and γ isoforms contribute to the pool of total IL-32 
in plasma and cells from HIV infected subjects. Of note, the isoforms IL-32β and γ in contrast to IL-32α and δ 
exhibit pro-inflammatory features25 thus raising the possibility that their over-expression is likely linked to the 
loss of control. Interestingly, plasma levels of total IL-32 were lower in EC subjects compared to TP (p < 0.05, 
Fig. 3c). These results suggest a positive association between the levels of the IL-32 isoforms, other than IL-32α 
and δ , and VL. This was further confirmed by measuring the level of total plasma IL-32 in SP subjects losing con-
trol (subjects identified in Fig. 2c, n = 17). As expected, total IL-32 was significantly higher in SP subjects losing 
virological control compared to subjects from the same cohort who maintained unchanged VL and a stable CD4 
between V1 and V2 (Fig. 3d). It was notable that total IL-32 levels at V1 were significantly higher in the SPs who 
were going to lose HIV control at V2 than they were in SP who maintained VL control (Fig. 3d) and these total 
IL-32 levels were positively correlated with the CD4 count change from V1 to V2 (delta CD4) (Spearman ρ = 0.41, 
p = 0.04, Fig. 3e).
Together, these results showed that while loss of CD4 counts and increased viremia in a subgroup of SP subjects 
is associated with a decrease in the IL-32α (confirmed at the protein level) and IL-32δ (data from the transcrip-
tomic analysis), there was a significant increase in the non-α /non-δ IL-32 isoforms that high likely included the 
pro-inflammatory isoforms β and γ . Furthermore, there was a significant correlation between levels of total IL-32 
and the degree of CD4 count decline as measured by magnitude of the decrease in CD4 counts from V1 to V2.
HIV infection increases IL-32 production. Total IL-32 levels in the different subgroups of HIV-infected 
subjects (EC, VC, NVC and TP Fig. 3c) were highly and significantly correlated with HIV VLs from these sub-
jects (Spearman ρ = 0.52, p < 0.0001, Fig. 4a). These results suggest that enhanced expression of IL-32 in the 
periphery of HIV-infected subjects is likely driven directly by viral infection. To test this hypothesis, total PBMCs 
from HIVneg donors were stimulated with PHA and IL-2 for 48 h followed by infection with the laboratory strain 
HIV-BaL for 3 extra days. In another set of experiments, total PBMCs were directly infected for 3 days without 
previous stimulations. As shown in Fig. 4b infection of either stimulated or unstimulated cells led to a significant 
up-regulation total IL-32 measured in the supernatant or as cell-associated protein, respectively (p = 0.003 for 
both). We further measured the levels of IL-32 in subjects with recent HIV infection. Total IL-32 levels in plasma 
from recently infected viremic subjects (n = 10 subjects infected for ≤ 3 months) were higher than that in the 
same subjects treated for 1 year with ART (p = 0.002) (Fig. 4c, Left panel), thus emphasizing the link between 
IL-32 and viral replication. Results in Fig. 4c (Right panel) demonstrate that even following 1 year of treatment, 
the total IL-32 levels remained significantly higher compared to HIVneg donors (n = 10 PHI and n = 12 HIVneg 
donors, p = 0.016). Together, our observations suggest that IL-32 is induced early after HIV infection and is not 
normalized by viral suppressive ART.
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Plasma levels of total IL-32 predict inflammation, CD4 decline and increased VL in SP sub-
jects. Our observation that total IL-32 levels are high in early HIV infection (Fig. 4c) and in SP subjects who 
experience loss of HIV control (Fig. 3d) and that these levels positively correlate with the decrease in CD4+ T-cell 
Figure 3. Loss of HIV control in SP subjects is associated with decreased IL-32α/δ and increased non-α 
non-δ IL-32 isoforms. (a) Line plot showing a summary of Log2 fold change in gene expression of 10 selected 
genes including IL-32α and δ from microarray analysis on n = 5 SP subjects who lost control (VC, n = 2 and 
NVC, n = 3). (b) Plasma levels of IL-32α measured by ELISA on EC and TP subjects compared to HIVneg 
controls (n = 9/group). (c) Total IL-32 (α , β , γ and δ ) measured by ELISA on HIVneg (n = 13), EC (n = 17), VC 
(n = 25), NVC (n = 11) compared to TP subjects (n = 16). (d) Total IL-32 in plasma from subjects losing control 
(n = 17) compared to subjects showing no decrease in CD4 counts or increase in VL (n = 13) at both V1, before 
loss of control (Left Panel) and V2, after loss of control (Right panel). The lines and error bars through each data 
set represent the mean ± SD for the group. (e) Correlation between the total levels of plasma IL-32 at V1 and the 
change in CD4 counts at V2 (delta CD4) for the n = 17 SPs who lost HIV control. Kruskal-Wallis and Dunn’s 
post tests were used to assess the significance of between-group differences in panels (b,c) Mann-Whitney tests 
were used assess the significance of between-group differences in panel (d) Spearman correlation tests were 
used to assess the significance correlations between the 2 parameters tested in panel (e).
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Figure 4. HIV infection induces expression of IL-32 in human PBMCs. (a) Correlation between total 
IL-32 and VLs from HIV-infected SP (n = 53) (EC, VC, NVC) and TP subjects (n = 16) (subjects shown in 
Fig. 3c). Spearman correlation test was used to assess the significance correlations between IL-32 and HIV 
VL. (b) Human PBMCs from n = 9 HIV-uninfected donors were either stimulated with PHA (0.25μg/ml) and 
IL-2 (100 units/ml) and infected with HIV-BaL (Left panel) or resting cells were infected without stimulation 
(Right panel). Total IL-32 was measured in the supernatant of activated cells (Left panel) or from cell lysate 
of non-stimulated cells (Right panel). (c) Total plasma IL-32 was measured in n = 10 subjects within 3 mos of 
HIV infection and after 1 year of ART treatment (Left panel). Total plasma IL-32 was measured in the same 10 
subjects treated with ART for 1 yr and in 12 HIVneg donors (n = 12) (Right panel). The significance of between-
group differences was assessed using a Wilcoxon test in panel (b) and the Left panel of (c). A Mann-Whitney 
test was used to assess the significance of between-group differences in panel (c) (Right panel).
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count from V1 to V2 (Fig. 3e), together with the proinflammatory nature of IL-32 non-α /non-δ isoforms25, led us 
to hypothesize that IL-32 levels may predict the loss of control in the general population of SP subjects. To test this 
hypothesis, we first confirmed the chronicity of IL-32 secretion by measuring its levels longitudinally in plasma 
from the SP subjects. Subjects with confirmed loss of control between V1 and V2 (Fig. 2c) were excluded from 
this analysis. We also measured other inflammatory markers such as sCD14, a marker of innate immune activa-
tion and a predictor of disease progression and mortality in ART-treated subjects26, and IL-6, an inflammatory 
marker that predicts ongoing HIV replication in vivo27. As shown in Fig. 5A, levels of total IL-32 at V1 and V2 
were positively correlated in the general population of SPs (Left panel, Spearman ρ = 0.73, p < 0.0001). Similarly, 
levels of both sCD14 and IL-6 at V1 and V2 were positively correlated (Middle and Right panels, respectively, 
Spearman ρ = 0.67, p < 0.0001 for sCD14, and Spearman ρ = 0.50, p = 0.0004 for IL-6). Moreover, total IL-32 
levels at both V1 and V2 were positively and significantly correlated with sCD14 levels in plasma from the same 
time points (Fig. 5B, Left and Middle panels). Most importantly, IL-32 levels at V1 significantly correlated with 
both sCD14 and IL-6 levels in plasma from V2 (Spearman ρ = 0.33, ρ = 0.39, and p = 0.0227 and p = 0.0067, 
respectively) (Fig. 5B,C, Right panels). These results suggest that IL-32 levels at V1 can predict levels of inflam-
matory markers at later time points.
In HIV infection the CD4/CD8 ratio is usually inverted (< 1) and is often used as a marker for HIV-associated 
immune dysfunction28–30. This ratio was negatively and significantly correlated with IL-32 levels at both V1 and 
V2 (Spearman ρ = − 0.50, ρ = − 0.39, and p = 0.0004 and p = 0.0066, respectively, Fig. 6a Left and Middle pan-
els). Furthermore, IL-32 levels at V1 were negatively correlated with CD4/CD8 at V2 (Spearman ρ = − 0.46, 
and p = 0.0013, Fig. 6a, Right panel). IL-32 levels at V1 further correlated negatively and significantly with CD4 
counts at V1 (Spearman ρ = − 0.32, and p = 0.027, Fig. 6b, Left panel). At V2, IL-32 showed a non-significant 
trend towards being negatively correlated with CD4 counts. However, as observed for the sCD14, IL-6 and CD4/
CD8 ratio, IL-32 at visit 1 negatively and significantly predicted CD4 counts at visit 2 (Spearman ρ = − 0.33, and 
p = 0.025, Fig. 6b, Right panel). Interestingly, neither sCD14 nor IL-6 at visit 1 could significantly predict CD4 or 
CD4/CD8 ratio at visit 2 (Supplementary Figs S6 and S7).
Based on our observation that HIV-infected typical progressors (viremic) have higher IL-32 levels com-
pared to HIV-infected aviremics (EC) (as shown in Fig. 3c) and the significant correlation between IL-32 and 
VL (Fig. 4a), we expected that IL-32 levels at V1 to positively predict higher HIV VLs at V2. As shown in Fig. 6c 
(Left and Middle panels) total IL-32 levels positively correlated with HIV Log10 VL at both V1 and V2 (Spearman 
ρ = 0.54, and p < 0.0001 for both). IL-32 at V1 further predicted the HIV burden at visit 2 (Spearman ρ = 0.38 
and p = 0.01 (Fig. 6c, Right panel). Finally, no correlation was observed based on age, sex or time between V1 and 
V2 (Supplementary Fig. S8).
Collectively, our results show that total IL-32 is a robust biomarker for loss of control, increased HIV burden 
and inflammation in the SP cohort.
IL-32γ compared to IL-32α has a proinflammatory profile consistent with enhanced HIV rep-
lication. IL-32 was initially described as an intracellular anti-viral factor23. However, our observations on 
correlations between total IL-32 (essentially non-α /non-δ isoforms) and inflammatory markers suggest that these 
isoforms may be implicated in mechanisms that promote HIV replication instead of exerting intracellular anti-
viral effects. This hypothesis is supported by earlier observations showing that IL-32γ -mediated inflammation 
can induce immune suppression by activating the production of Indoleamine 2,3-dioxygenase, IDO131. We next 
investigated the impact of IL-32γ , compared to IL-32α (the only available recombinant isoforms of IL-32) on the 
activation of primary T-cells by measuring a panel of secreted inflammatory and anti-inflammatory cytokines 
following TCR activation. The panel included IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17 A, IL-17 F, IL-22, 
TNFα and IFNγ ). CD4+ T-cells isolated from HIVneg donors or HIV-infected subjects were stimulated with CD3/
CD28 antibodies to engage the T-cell receptor in the presence or absence of either IL-32α or IL-32γ . Supernatants 
collected 48 h after stimulation showed that both IL-32α and IL-32γ had an additive effect on TCR stimulation. 
The effect of IL-32γ on the cytokine production by T-cells from both HIVneg and HIV-infected subjects was supe-
rior to that of IL-32α (Fig. 7 and Supplementary Table S3). In line with previous reports on other cell types32,33, 
IL-32γ induced significantly higher levels of IL-6 in CD4+ T-cells, consistent with the in vivo data depicted in 
Fig. 5C. More importantly, IL-32γ induced higher levels of IL-17 A and IL-17 F upon stimulation of CD4+ T-cells, 
which indicates a specific activation of Th17 cells, a CD4+ T-cell subset documented to be highly permissive to 
HIV infection34–36. Similar results were obtained from CD4+ T-cells isolated from both HIVneg and HIV+ subjects 
(Supplementary Table S3).
Together, these results demonstrated the greater potency of IL-32γ compared to IL-32α for stimulating 
inflammatory cytokines and further confirm the association between IL-32 and IL-6 that we observed in vivo in 
our cohort of SP subjects. The results also suggest a novel role for IL-32 in promoting activation and/or expansion 
of Th17 cells that are susceptible to HIV infection.
Discussion
In the current study we showed that among the HIV-infected SPs, EC experienced the lowest rate of CD4+ T-cell 
decline and the lowest frequency of subjects showing loss of virological control. This was further confirmed by 
setting a threshold of CD4+ T-cell decline to 100 cells/mm3 combined with increased Log10 VL between distal 
clinic visits with an average time interval of up to 3 years. The EC subgroup compared to VC and NVC showed 
a statistically significant superiority in maintaining sustained VL and stable CD4 counts. This could not be 
explained by the distribution and frequency of protective MHC class I antigens such as HLA-B*27 and B*57 
within each subgroup, as the between group differences were not statistically significant. However, by comparing 
the whole SP group to HIV-infected TP, SPs had statistically higher frequencies of protective MHC class I.
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Host genetic factors have been implicated in the control of HIV pathogenesis as evidenced by the higher 
frequency of protective HLA alleles (HLA-B*27, HLA-B*51, and HLA-B*57) in SPs15,16,37. Specifically, in 
treatment-naive populations, steady-state VL can be in part explained by human genetic variations, with cer-
tain single nucleotide polymorphisms (SNPs) at the HLA B and C loci being associated with lower viral loads 
(VL)38. However, the variable disease progression observed among aviremic controllers who maintain undetect-
able viremia39, combined with the lack of disease progression in another subset of subjects with moderate levels 
of HIV-RNA, would then suggest that clinical progression and viral control may represent distinct phenotypes. 
In agreement with these observations, our results showed that several SP subjects who lost virological control had 
at least one HLA protective allele, thus pledging for other detrimental factors to be implicated in the control of 
disease progression. Among these potential factors, persistent low level of inflammation might be a major drive 
for disease progression within the different subgroups of SPs39. SPs have a low but significant level of immune 
activation that is likely induced by persistent exposure to HIV. D-dimer, soluble CD163 and lymphoid tissue 
Figure 5. Persistent levels of IL-32 predict inflammatory and clinical markers. (A) Correlations between 
individual inflammatory markers, total levels of IL-32 (Left panel), sCD14 (Middle panel) and IL-6 (Right 
panel), measured in plasma from the same EC (n = 19), VC (n = 22), NVC (n = 6) subjects at V1 and V2. 
Correlations between total IL-32 at V1 and V2 with sCD14 (B) and IL-6 (C) at V1 and V2 on the same subjects 
as in panel (A). A Spearman correlation test was used to assess the significance of correlations between the 2 
measured parameters. The correlation coefficient (ρ ) and p-value for.
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fibrosis were all reported to be increased in EC subjects40. Interestingly, by employing genome-wide transcrip-
tional analysis and in vitro and in vivo validation of protein expression on primary cells from SPs losing virologic 
control, we showed that the proinflammatory cytokine IL-32 is modulated at the transcriptional level. Upon loss 
of control, there was a significant decrease in the less active inflammatory isoforms of IL-32 and, in contrast, an 
increase in the more proinflammatory isoforms.
IL-32 is a relatively newly identified cytokine that was initially known as the Natural Killer induced transcript 
4 (NK4), which is selectively expressed in NK and T-cells upon stimulation with IL-2 and mitogens, respectively41. 
The biological functions of the protein encoded by this NK4 transcript were consistent with that of a cytokine. 
NK4 was renamed IL-32 following the discovery of its typical proinflammatory features, as it induces a panel of 
Figure 6. Plasma IL-32 levels predict typical clinical parameters associated with disease progression in SP 
subjects. Correlations between plasma levels of total IL-32 measured for the same subjects as in Fig. 5 and CD4/
CD8 ratio (a), absolute CD4+ T-cell counts (b) and HIV Log10 VL (c) at V1 (Left panels), V2 (Middle panels) 
and V1 versus V2 (Right panels). A Spearman correlation test was used to assess the significance of correlations 
between the 2 measured parameters. The correlation coefficient (ρ ) and p-value for each comparison are shown 
over the graphs.
www.nature.com/scientificreports/
1 2Scientific RepoRts | 6:22902 | DOI: 10.1038/srep22902
other inflammatory cytokines including TNFα , IL-8, IL-6 and macrophage inflammatory protein-2 (MIP-2)32,33,42. 
The majority of these functions are mediated by the specific activation of signaling pathways involving p38 
mitogen-activated protein Kinase (MAPK) and nuclear factor NF-κ B as well as activator protein-1 (AP-1)23. 
Interestingly, IL-32 is expressed in at least 9 different isoforms (α , β , γ , δ , ε , ζ , η , ς and θ ) generated by alternative 
splicing43. The γ protein is the longest (full protein) and most active pro-inflammatory isoform and the α isoform 
is the shortest and least active one44. Information on the detailed functions of these individual isoforms and their 
corresponding receptors and the reason why there are as many as 9 different protein isoforms remain unclear. 
However, some evidence suggests that splicing of the full γ protein to shorter isoforms represents a safety switch 
mechanism to protect against uncontrolled and exaggerated inflammation25.
IL-32 was initially shown to play a potential antiviral role at the intracellular level, as targeting IL-32 with 
RNA interference significantly increases HIV replication23,24. However, RNA interference was not targeting spe-
cific IL-32 isoforms but rather the total protein. The antiviral activity of IL-32 in this context was essentially 
mediated through interferon type I and II and interferon-stimulated genes (ISGs)23. Interestingly, the beneficial 
role of the modest anti-HIV activity of IL-32 was later challenged with in vivo data from HIV-infected subjects. 
Smith et al.31 clearly showed that IL-32 expression is highly detectable in lymphoid tissues from HIV+ subjects 
representing all stages of infections; acute, asymptomatic and AIDS. In these lymphoid tissues, IL-32 induces the 
immunosuppressive enzyme indoleamine 2, 3-dioxygenase (IDO) and the negative regulatory protein Ig-like 
transcript 4 (ILT4) and hence positively correlates with enhanced viral replication and decreased CD4+ T-cell 
Figure 7. IL-32γ enhances Th1 and Th17 cytokine secretion from CD4+ T-cells stimulated through the 
T-cell receptor. CD4+ T-cells were isolated from HIVneg (n = 3) and HIV-infected ART-treated subjects (n = 3) 
by negative selection and stimulated with plate-bound anti-CD3 (0.5 μg/ml) and anti-CD28 (0.5 μg/ml) in 
the presence or absence of either IL-32α (500 ng/ml) or IL-32γ (500 ng/ml). Shown on these bar graphs are 
cytokine levels secreted following activation through the TCR alone (set at 100%) or in the presence of either 
IL-32α or IL-32γ . Bar height and error bars represent the mean ± SD for a combined group of n = 3 HIVneg 
and n = 3 HIV-infected ART-treated subjects. Kruskal-Wallis and Dunn’s post tests were used to assess the 
significance of between group cytokine levels when IL-32α or IL-32γ were present in addition to the anti-CD3/
CD28 TCR stimulus. *p < 0.05, **p < 0.001, ***p < 0.0001.
www.nature.com/scientificreports/
13Scientific RepoRts | 6:22902 | DOI: 10.1038/srep22902
survival. This marked effect was shown to be mediated by IL-32γ as shown by their in vitro data. This is in line 
with our current observations that the least active isoform of IL-32 (IL-32α ) is indeed decreased and, in contrast, 
the non-α proinflammatory isoforms are significantly increased in HIV infected SPs experiencing loss of VL 
control and also from HIV-infected primary cells in vitro. Increased protein levels of the non-α IL-32 isoforms 
was evidenced by the detection of increased levels of total IL-32 using antibodies having the capacity to recognize 
the four major isoforms (α , β , γ , δ ) meanwhile a decrease in the protein levels of the α isoform (detected with 
α -specific antibodies). As our transcriptomic data on subjects with control failure also showed a decrease in the 
IL-32δ isoform, the aforementioned increase in total IL-32 is high likely due to increased levels of IL-32 β and γ . 
However, the relative contribution of each of these two isoforms in the increased levels of IL-32 upon loss of 
control was not determined in the current study due to technical difficulty. Our observations on the abundance 
of the proinflammatory non-α isoforms of IL-32 in HIV-infected subjects compared to HIV-negative donors, 
who in contrast have higher levels of the less inflammatory isoform α , are consistent with earlier reports on 
the differential expression of IL-32 isoforms under inflammatory conditions45. However, a study by Monteleone 
et al.46 reported increased expression of all IL-32 isoforms including both α and non-α isoforms, in HIV-infected 
compared to HIV-negative individuals. Although these studies were carried out only on the transcriptional level 
(mRNA) without validating the protein expression of the different isoforms of IL-32, they might suggest that 
post-transcriptional modifications of isoform expression may take place in HIV infection to favor the expression 
of the non-α isoforms. Further studies at the molecular level are then warranted to understand the underlying 
mechanisms of differential IL-32 isoform expression upon loss of HIV control and increased viral load. In this 
regard, it remains unclear how HIV modulates the transcription of IL-32 to increase the pro-inflammatory and 
decrease the less inflammatory isoforms. It is also unclear how and when these proinflammatory isoforms drive 
loss of control in HIV-infected subjects with history of disease control. This remains an open question that we 
will tackle in future studies measuring longitudinally the modulation of IL-32 expression from these subjects.
Sustained inflammatory environment is likely to be advantageous for HIV replication. Our in vitro data show-
ing activation of CD4+ T-cells by IL-32γ suggest that IL-32 might enhance HIV replication. In this regard, IL-32γ 
induced high levels of both IL-17 A and IL-17 F, two cytokines produced by Th17 CD4+ T-cells, which are major 
players in mucosal immunity and that are depleted in HIV infection34,47,48. These data are in line with previous 
reports linking IL-32γ inflammation with increased Th1 cytokines and induction of Th17 polarizing cytokines by 
phospholipase C/JNK and NF-κ B dependent mechanisms49. Interestingly, by using Gene Set Variation Analysis 
(GSVA)50 on our microarray data from subjects losing control, we identified an increase in the inflammasome and 
loss of Th17 pathways as a top hit (data not shown). This may suggest that sustained inflammation and activation 
of Th17 cells by IL-32 and potentially productive HIV infection may contribute to a significant depletion of these 
cells in vivo. Th17 cells play a central role in mucosal immunity and depletion of these cells underlies the marked 
mucosal insult, microbial translocation (MT) and associated pathologies in HIV-infected subjects34,51,52. On its 
turn, MT is associated with systemic circulation of different bacterial products, including lipopolysaccharides 
(LPS), leading to chronic innate immune activation (CI)53–56. One of the major consequences of CI is the persis-
tent activation of monocytes by LPS56. Monocytes actively respond to LPS by up-regulating and releasing the LPS 
co-ligand, the soluble CD14 (sCD14)57. Interestingly, our studies showed that increased IL-32 levels in SP subjects 
is associated with increased sCD14 and further links this to the activation and potential depletion of Th17 cells. 
More importantly, our results show a strong predictability of both inflammation (as shown by IL-6 and CD4/
CD8 ratio) and sCD14 levels by IL-32 over periods that ranged from few months to few years, thus placing IL-32 
upstream of these pathways. This is further supported by the strong correlation but also the predictability of CD4 
decline and increased VL by total IL-32 levels in the periphery of SP subjects. Deterioration of these two major 
clinical factors is then likely linked to the IL-32-mediated inflammation and pathology (impact on Th17 cells) and 
suggests circulating IL-32 as a potential therapeutic target.
In summary, our current report highlights an unappreciated role for the recently described cytokine IL-32 in 
disease progression in HIV-infected SPs. IL-32 significantly correlates with the loss of virological control and CD4 
decline in these SP subjects and furthermore could reliably predict this loss of control over a period of time that 
ranged from few months to several years. Our proof-of-concept for the predictability of disease progression by 
the plasma levels of IL-32 then warrants further investigations in the general population of HIV-infected subjects 
including those under treatment. We also suggest that IL-32 may represent a potential therapeutic target to pre-
vent persistent inflammation and its associated pathologies in the HIV-infected population.
Methods
Study cohort. Our study is focused on the CCHSP that was launched in 2005 and is currently enrolling 
treatment-naive study participants from 18 centers across Canada. HIV infected SPs, defined according to the 
characteristics presented in Table 1, were enrolled to the study following written informed consent if they met 
the following inclusion criteria: 1) HIV positive by ELISA with a confirmed Western Blot 2) 18 years and older 3) 
had never received ART. In addition, a treatment-naive “control” cohort was simultaneously enrolled during HIV 
primary infection and followed up to 2 years.
Demographic and disease history data collected at baseline included age, sex, race, mode of transmission, age 
at diagnosis, date of diagnosis and number of years infected at baseline, and information on HIV risk behaviors 
and drug use. Baseline assessments included a physical exam signs and symptoms of HIV infection. In addition, 
the disease trajectory for each study participant was also established using abstracted data on all CD4 counts and 
HIV-RNA VLs from the medical charts. Four weeks after the baseline evaluation, study participants provided a 
medical history update and underwent routine biochemistry and hematology blood work and CD4+ and CD8+ T 
cell counts, including subset percentages and provided samples for HIV-1 DNA assays. Finally, 135 mL of whole 
blood was collected at the one month assessment to conduct genetic analyses for genetic polymorphism in genes 
associated with slow disease progression, including MHC class I HLA- B*14, -B*27, -B*38, -B*51, -B*57, -B*58, 
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-B*8116–18. Genotyping was done as previously described58. At each subsequent follow up visit, study participants 
underwent a routine physical exam and provided blood specimens for routine chemistry and hematology and 
study-specific CD4+ T-cells and HIV-RNA assays. Study participants were seen at baseline and then at months 
1, 6, 7 and 12 during the first year of the study. Participants continued to be seen according to the same schedule 
(twice every six months, one month apart) for a total of five years. Study participants were then re-consented to 
continue to be followed under an optional extension study.
Study participants were excluded from the study if they chose to initiate ART, failing to keep appointments or 
missing 2 study visits in a row or if they wished to be removed from the study. Subjects necessitating ART initi-
ation as indicated by their physician, were maintained in the study. In study participants receiving ART, clinical 
and laboratory data continued to be collected according to the study schedule, however research blood draws 
were only performed once a year.
Data collected prospectively as part of this study was then combined with historical data from the medical 
charts at the time of enrolment to establish the disease trajectory for each study participant. Disease progression 
was defined as a significant negative CD4 slope combined with a significant positive VL slope calculated on his-
torical and prospective clinical records since the time of infection for each subject. Loss of control between visits 
was calculated for each subject as having a loss of CD4 counts ≥ 100 cell/mm3 combined with any increase in the 
Log10 VL.
Study approval. This study was approved by the Institutional Review Boards (IRB) of the Centre Hospitalier 
de l’Université de Montréal Research Center and at all participating sites’ IRBs. All experiments were performed 
in accordance with the guidelines and regulations approved by the ethic committees from CRCHUM and all IRBs 
(Ethical approval #SL 04–061). Study participants provided written informed consent for the use of their plasma 
and cells for the current research investigation.
Transcriptomic analysis by microarray. Total cellular RNA was extracted from PBMC of selected 
HIV-infected SPs using the RNeasy columns kit (Qiagen Cat # 74104), according to the manufacturer’s directions, 
followed by quality assessment and quantification. RNA reverse transcription and gene expression profiling from 
V1 and V2 (before and after loss of control) from n = 5 SP subjects was carried out on the microarray platform of 
the Génome Québec Innovation Center (Montreal, QC, Canada). The platform uses the Illumina HumanHT-12 
v4 Expression BeadChip that provides more than 47,000 transcripts and known splice variants across the human 
transcriptome. Data generated by the Illumina Bead arrays were first inspected for errors followed by a series 
of exploratory data analysis methods that are used to identify the potential sources of expression variation or 
bias (PCA/ICA, MDS, SVA), and identification of potential technical or biological outliers (hierarchical clus-
tering). Proper normalization or transformation of the data was customized based on the observed results and 
needs. For differential gene expression, moderated t-statistics were calculated using multiple regressions with 
the inclusion of known covariates or new ones identified in the exploratory phase. This analysis was performed 
with the Limma software suite59. Differentially expressed genes with a cut-off value greater than 1.3-fold and a 
statistical p value < 0.05 were considered for further analysis. The gene networks for candidates of interest were 
generated through the use of Ingenuity Pathways Analysis (Ingenuity® Systems, www.ingenuity.com) and Gene 
Set Variation Analysis (GSVA).
HIV VL, absolute T-cell counts and genetic polymorphism determinations. Blood samples were 
collected in EDTA tubes from study participants undergoing routine laboratory measures. Absolute CD4 and 
CD8 T-cell counts were obtained using BD FACSCount reagent Kits according to manufacturer’s directions 
(standardized clinical measures). The Antibody mixture for absolute counts contained custom-made antibodies 
specific for CD3, CD4, CD8, CD19 (to exclude B cells), CD56 (to exclude NK cells), CD45RA and CD38 (for cell 
activation profile). HIV plasma VL was determined by the ultrasensitive assay Amplicor (Roche) with a range of 
amplification of 50–750,000 copies/ml.
Measurements of soluble proteins and cytokines. Plasma samples from HIV-infected and HIVneg 
subjects were used to quantify human soluble CD14 (sCD14) using Quantikine ELISA Kit (R&D Systems, Cat 
# DC140), total IL-32 by DuoSet Human IL-32 (R&D Systems, Cat # DY3040), IL-32 alpha isoform using com-
petitive Human Interleukin 32α (IL-32α ) Elisa kit (MyBioSource, Cat # MBS750027), IL-6 using Human IL-6 
ELISA Ready SET-Go (eBioscience, Cat # 88-706622), according to the supplier’s protocol. Cell-associated total 
IL-32 was measured by ELISA from cell lysates prepared as follows: total PBMCs from HIV+ or HIVneg subjects 
were lysed by 1X RIPA buffer (Cell Signaling, Cat #9806) supplemented with protease inhibitors (Roche, Cat # 04 
693 159 001 and 04 906 837 001) followed by quantification of total protein per lysate using the Bradford assay60. 
ELISA measures from total cell lysate were normalized to the total protein in the lysate and plotted on graphs as 
IL-32 pg per 1μg of total cellular protein.
Cell purification, stimulation and infection with HIV-1. CD4+ T-cells were isolated from total PBMCs 
by negative selection using EasySep Human CD4 T Enrichment columns (StemCell, Cat #19052). Purity of CD4 
was typically > 98% as determined by surface staining of CD4+ T-cells with CD3-Pacific Blue (UCHT1) and 
CD4-Alexa Fluor 700 (RPA-T4), (both from BD) and FACS analysis (BD LSRII analyser). Purified CD4+ T-cells 
were stimulated with plate-coated anti-CD3 antibody (0.5μg/ml) and soluble anti-CD28 antibody (0.5μg/ml) 
(both from BD Biosciences, Cat ##555329, 5555726 respectively) for 48 h in the presence or absence of 500 ng 
IL-32α (BioLegend, Cat # 551004) or IL-32γ (R&D Cat # 4690-IL-025/CF). Secreted cytokines were meas-
ured from the supernatant of activated cells using the LEGENDplex™ Human Th Cytokine Panel (13-plex) 
(BioLegend, Cat # 740001) according to manufacturer’s directions. Infections of PBMCs stimulated with PHA 
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and IL-2 (0.25μg/ml, and 100 units/ml, respectively) or resting cells were carried out using 50 ng of the laboratory 
strain HIV-BaL per 106 cells by Spinoculation61 (2 hours/Room temperature). Following infection, PBMCs were 
washed twice by PBS and centrifuged at 1500 rpm for 5 min then were re-suspended in RPMI-1640 medium 
supplemented with 10% FBS. Cells were kept in culture for 48 h before collection of supernatants and cells for 
cytokine measures.
Statistical analysis. Data were analyzed using GraphPad Prism 4 (GraphPad software, San Diego, 
CA). Data from the same subjects before and after observation were analyzed using Wilcoxon matched pairs 
test. Comparison between 3 or more groups for the same observation was done with the non-parametric 
Kruskal-Wallis test followed by Dunn’s post tests to investigate difference between paired groups. Differences 
between two groups of subjects for the same observation was done using the non-parametric Mann-Whitney. 
Any other methods are described as appropriate in the text.
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